RU2108786C1 - Agent for treatment of oncological patients - Google Patents

Abstract

FIELD: medicine, oncology. SUBSTANCE: invention proposes an agent for treatment of oncological patients - amino acid L-tryptophan or its derivative - 5-hydroxy-N,N-dimethyltryptamine. EFFECT: broadened assortment of agents for oncological patients treatment. 6 ex

Description

 The invention relates to medicine, in particular to oncology, and can be used in the treatment of patients with malignant diseases.

 Currently known treatment methods, such as surgical treatment, radiation therapy, hormone therapy, chemotherapy (Antitumor therapy. - M.: Medicine edited by N.I. Perevodchikova). The latter is essentially the closest analogue of the invention.

 All these types of treatment are ineffective and give numerous complications (Gershanovich M.L. Complications during chemo-and hormotherapy of malignant tumors. - M .: Medicine, 1982).

 According to the author, none of the indicated treatment methods has a distinct biomedical connection with the etiopathogenesis of the disease and the cause of the development of immunodeficiency in these conditions, and none of the indicated treatment methods is aimed at restoring the function of the immune system.

 The invention is based on the author's theoretical assumptions that the development of cancer is preceded by a metabolic disorder in the body that is progressing, leading to a state of immunodeficiency. In particular, there is a metabolic disorder involving phenylalanine and tryptophan, which in turn cause the development of oncological diseases of certain histological structures.

The essence of the invention consists in the use in the treatment of patients with malignant tumors of preparations of L-tryptophan or 5-hydroxy-N, N-dimethyltryptamine. L-tryptophan (a-amino-3-indolpropionic acid) C ₁₁ H ₁₂ O ₂ N ₂ Mm 204.22 crystallizes in the form of plates and leaflets from diluted C ₂ H ₅ OH. Solubility: 1.14 ²⁵ , 2.80 ⁷⁵ , 4.98 ¹⁰⁰ H ₂ O; soluble in hot pyridine, diluted alkalis, slightly soluble in C ₂ H ₅ OH; not soluble in CHCl ₃ , ether, mp. 281-282 ^o С (289 ^o С) (Kalinin F.L. et al. Handbook of biochemistry.- Kiev: Naukova Dumka, 1971, p.139). Previously, it was not used for therapeutic purposes.

 Phenylalanine catabolism begins with hydroxylation with the phenylalanine-4-monooxygenase enzyme; tyrosine is the reaction product. If protein synthesis of this enzyme is impaired, minor pathways of phenylalanine metabolism become less pronounced, which are little used in healthy people.

 In the absence of the enzyme, transamination occurs and phenylpyruvic acid is synthesized. The accumulation of phenylpyruvic acid leads to the formation and urinary excretion of phenyl lactic acid, O-hydroxyphenyl lactic and phenylacetic acid (White A. et al. Fundamentals of Biochemistry. - M .: Medicine, 1981, v. 2, p. 888, White A. et al. Fundamentals of Biochemistry. - M .: Mir, 1981, vol. 2, p. 362, Archives of Disease in Child hood VS1 p.771-777, 1976; Chemical Absfracts, 1969, v. 71, N 36868, p.149- 152). The accumulated products of pathological metabolism cause a state of chronic intoxication, which leads to the development of immunodeficiency and to the collapse of the immune system. These disorders cause the development of cancer. The synthesis of phenylalanine and tryptophan in microbes has a common horizon: chorismic acid, being its end product of metabolism (White A. et al. Fundamentals of Biochemistry. - M .: Medicine, 1981, v. 2, p. 888). They have the properties of mutual influence on gene initiation and information transfer to ribosomes for the synthesis of absent protein in mammals (White A. et al. Fundamentals of Biochemistry. - M .: Mir, 1981, v.2, p. 362).

 When phenylalanine is administered, tryptophanpyrrolase is induced. When prescribing tryptophan, a gene is initiated to read information and transfer it to ribosomes for protein synthesis of the missing enzyme (phenylalanine-4-monooxygenase). With acquired phenylketonuria (the absence of the phenylalanine-4-monooxygenase enzyme), L-tryptophan is prescribed for metabolic correction, which is initiated by a gene for transmitting information for protein synthesis of the missing enzyme.

 The biologically active substance L-tryptophan corrects this metabolism (phenylalanine metabolism), the products of pathological metabolism are excreted by the body and, thus, chronic intoxication is stopped and immunodeficiency is eliminated. The metabolites of restored cellular metabolism initiate the synthesis of neurohormones, and therefore, the synthesis of tropic hormones in the anterior pituitary is normalized. Thus, the function of the peripheral endocrine system, the function of negative feedback and the integral function of the neuroendocrine system are restored, and this in turn leads to the normalization of the function of the immune system, to the cure of malignant neoplasms.

 Example 1. Patient B., 38 years old, Moscow. Worked in the ZIL foundry. Regarding ovarian endometriosis, she was registered with the ZIL Polyclinic for 6 years before the operation, of which she received hormone therapy with 17-hydroxyprogesterone capronate for the last two years. In May 1993, surgical treatment was offered, which the patient refused. In January 1993, the condition worsened, abdominal pain intensified, and weakness appeared. She was sent to the gynecological department at the ZIL hospital. During the examination, laparoscopy was performed: ovarian cancer was detected with the formation of a tumor conglomerate in the region of the right appendages, ascites, dissemination along the visceral peritoneum. A puncture of the posterior fornix was made, cytologically: adenocarcinoma. When viewing drugs in the Gorkonodispanser - an adenocarcinoma. 11/01/94 was hospitalized in the Department of Oncogynecology of the Moscow Research Institute of Herzen P.A., where on 10.02.94 the operation of hysterectomy with appendages, resection of the greater omentum was performed. Histology: in both ovaries, overgrowth of adenocarcinoma. In the postoperative period, 3 courses of polychemotherapy were performed. From X to XII took L-tryptophan. At this time, there are no relapses and metastases. Without treatment with tryptophan, which ultimately restores the function of the immune system, progression was inevitable.

 Example 2. Patient Ch., Born in 1927, Dolgoprudny.

 From the anamnesis it is known that the patient suffered from chronic colitis over the past three years, which caused exacerbations in the form of diarrhea and periodically intensifying pains in the left lower abdomen. With exacerbations of colitis, sulgin was taken, which partially gave an effect. In November 1995, irrigoscopy was performed, which did not reveal a tumor formation. 01/30/96 was hospitalized in the surgical department of 1 KGB, where on 04/04/96, a sigmoid colon revealed an overgrowth of an exophytic tuberous tumor growing along the perimeter of the intestine in the sigmoid colon. A biopsy was performed: pieces of a villous tumor with malignancy.

 02.16.96 an operation was performed in the s / s sigmoid colon: a 8x8 dense-elastic tumor that sprouted serosa in a separate area 1 cm in diameter. Separate lymph nodes 1.0-0.5 cm in the sigma mesentery. 10 cm backward and upward from the tumor, Sigma removed with the tumor. An anastomosis is laid end to end. Histology - adenocarcinoma with ulceration and decay. Tumor tissue sprouts the entire thickness of the intestinal wall. The clinical diagnosis is cancer of the sigmoid colon, stage III. Treatment to restore the function of the immune system was carried out by L-tryptophan IV-VI 96. At this time, relapses, metastases are not detected, the condition is satisfactory.

The active substance is 5-hydroxy-N, N-dimethyltryptamine C ₆ H ₁₆ O ₂ , crystals in the form of tablets or enemas. Solubility: o.r. With ₂ H ₅ OH acids, alkalis; about. with. ethyl ether; Нp Н ₂ О, mp 146-147 ^o C. (Chemical Encyclopedia. - M.: Soviet Encyclopedia, 1988, v.1, p.339; Kalinin F.L. et al. Handbook of Biochemistry. - Kiev: Naukova Dumka, p.69; Z Franke et al. Chemistry of Poisoning Substances, 1977, vol. 1, p. 361, 403-404, vol. 2, pp. 142-143, Encyclopedia of the alcaloids, ed. By I. Glasby, v. 1, N - Y., 1975, p.217, Federation Prtceedings N 20, p.885-888, 1961.

 The use of this drug allows the correction of tryptophan catabolism along the serotonin pathway through methylation of 5-tryptophanecarboxylase with a methylated metabolite. (B. Alberta, D. Bray and others. Molecular biology of the cell. - M.: Mir, t.3, s.288-290).

 This process carries out self-regulation of this exchange according to the allosteric type, discovered by French scientists in 1963-65. (Monod I., Changens IP., Iacob FIMol.biol. N 6, p. 306-329, 1963; Monod I., Wgman I. Changens IP Mol. Biol. N 12, p. 88-118, 1965) .

 The restored tryptophan exchange by the serotonin interstitial exchange leads to the normalization of the synthesis of methylated metabolites, including 5-hydroxy-N, N-dimethyltryptomine, which corrects the tryptophan exchange along the serotonin pathway.

 When this metabolism is restored, the body is gradually released from the accumulated products of pathological metabolism, and chronic intoxication ceases. Normal metabolites of cell metabolism initiate the synthesis of neurohormones and tropic hormones by the pituitary gland. The function of negative feedback and the integral function of the neuroendocrine system are restored. Immunodeficiency is eliminated, and the function of the immune system is restored, which leads to the prevention of the development and progression of malignant neoplasms.

 All of the above is confirmed by experimental data conducted at the Institute of Antibiotics in 1981-82. (Journal of Antibiotics and Chemotherapy, vol. 36, No. 4, pp. 54-55, 1991).

Clinical data:
Example 4. Patient Sh., Born in 1954, on October 15, 85, was operated on for a cyst of the right ovary. Histology: adenocarcinoma. Conducted 2 courses of monotherapy with thiothef. 07/05/86 - relaparotomy, left appendages removed and a large omentum resected. No cancer cells were found in the removed organs. Conducted another 2 courses of monotherapy with thiothef. 07/06/86 diagnosed with tumor recurrence in the left parametrium. 3 courses of chemotherapy were carried out, but the tumor began to progress against the background of the third course. The patient since 17.11. on 11/22/96 she took 5-hydroxy-N, N-dimethyltryptamine. The tumor regressed. Alive, healthy, able-bodied for the twelfth year.

 Example 5. Patient N., born in 1954, 13.10.85 diagnosed with a tumor of the anterior mediastinum. A puncture was performed through the anterior wall of the trachea. Punctate cytology: malignant tumor (lymphosarcoma). Six courses of polychemotherapy and a course of radiation therapy on the mediastinum after tumor recurrence were performed. The patient took 5-hydroxy-N, N-dimethyltryptamine from March 16 to 05.86. The tumor completely regressed. Repeated courses of treatment were not carried out. At this time, she is alive, healthy, able-bodied.

 Example 6. Patient H., p. 1927, 03/15/88, produced diagnostic curettage for uterine bleeding. Histology: adenocarcinoma. Endometrium, 04/12/86 The uterus with appendages was extirpated.

 Histology: adenocarcinoma. 07/23/88, in the left parametria diagnosed with relapse of the tumor. From July 28 to September 15, 88 a course of radiation therapy for the right and left parametrium was carried out. Discharged with a final diagnosis: continued tumor growth. The drug 5-hydroxy-N, N-dimethyltryptamine was taken from September to December 1988. The tumor regressed. At this time, alive, healthy.

 Example 7. Patient Sh., B. 1923, 10/13/89 biopsy was performed for a tumor of the bladder. Histology: transitional cell carcinoma stage I anaplasia. The patient refused traditional treatment methods. He took 5-hydroxy-N, N-dimethyltryptamine for three months from 1.11.89 to 4.02.90. A control biopsy was performed. Histoanalysis: no cancer cells found. At this time, alive and well. No additional courses or other treatments have been performed.

 Thus, the proposed funds L-tryptophan and 5-hydroxy-N, N-dimethyltryptamine, being biologically active substances, restore impaired metabolism, which is the cause of the developed immunodeficiency. Depending on the degree of differentiation of the malignant neoplasm, that is, taking into account the pathomorphological nature of the disease, which in turn depends on a violation of the ketabolism of amino acids, the patient is prescribed treatment with one or another drug. The duration of treatment depends on the age of the patient and is selected empirically in accordance with the data on the restoration of impaired metabolism.

Claims (1)

 Use of L-tryptophan or 5-hydroxy-NN-dimethyltryptamine as an agent for the treatment of cancer patients.